Summary by Moomoo AI
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated March 23, 2023, with details from its quarterly report filed on August 13, 2024. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial information and should be read in conjunction with the original prospectus. The Quarterly Report details the company's financial position, including a net loss of $14.3 million for the six months ended June 30, 2024, and a working capital deficit of $16.0 million. The company has incurred losses of $139.8 million since its inception and continues to face a high degree of risk. The report also includes unaudited condensed consolidated financial statements and notes, which outline the company's assets, liabilities, stockholders' deficit, and comprehensive loss for the period.
